The work continues
After the sale of Dianova in 2020, Jürgen Frerichs continued his scientific work at ONCOdianova. Established product names, catalog numbers, datasheets and distribution channels were carried forward. This preserved familiar scientific references and the unambiguous identification of the clones.
That history is still visible today in publications and antibody panels. The name Dianova can still appear there, because the clones concerned were documented under that name for many years and became established in research.
One example is the anti-TIGIT clone TG1, which can still be listed with historical Dianova details in more recent scientific sources.
ONCOdianova products continue to be offered through BIOZOL. That is another reason why familiar Dianova designations remain visible in product and ordering information.
Tissue as the scientific benchmark
For Jürgen Frerichs, what mattered in antibody development was how an antibody performs in tissue. A suitable research antibody should make its target clearly and reproducibly visible in formalin-fixed, paraffin-embedded tissue while preserving the spatial context of the tissue.
In immuno-oncology in particular, this information is especially valuable. It makes it possible to study biomarkers not in isolation but in the interplay of tumor cells, immune cells and other components of the tumor microenvironment.
His view of the ideal research antibody
For him, a high-quality research antibody combines unambiguous target recognition with a clear staining pattern, a convincing signal-to-background separation and reproducible results under defined conditions.
Equally important is the ability to combine different markers with one another. That is why human FFPE tissue, brightfield IHC, fluorescence multiplex IHC and further tissue-based research methods are central at ONCOdianova.
Experience as the basis for further development
This scientific attitude shapes the ONCOdianova portfolio to this day. The existing clones form the basis for the continuous development of distinctive research antibodies for relevant biomarkers and checkpoint axes.
The aim is to give researchers tools with which human tissue and its spatial biological relationships can be examined precisely.
